Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | CASP6 | P55212 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293002 | 0.77 | PDE10A (0.36) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1668366 | 0.75 | PIN1 (0.39) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12777859 | 0.75 | ALDH1A1 (0.42) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL251217 | 0.75 | SOS1 (0.37) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1265708 | 0.75 | ROCK1 (0.50) | MAPTHSP90AA1HSP90AB1LMNAROCK1 | |
| SCHEMBL28033503 | 0.75 | PDE10A (0.35) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7695777 | 0.75 | KMO (0.44) | TDP1 | |
| SCHEMBL3862889 | 0.71 | ALDH1A1 (0.44) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12344042 | 0.71 | ALDH1A1 (0.42) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12341060 | 0.71 | ALDH1A1 (0.36) | MAPTKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558496-A1 | NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119320495-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024017863-A1 | NOVEL PYRIMIDINYL AND TRIAZINYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | LIGAND UK DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-12-29 | — | — | US | disclosed |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-01-21 | — | — | US | disclosed |
| US-20190031668-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9765080-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20170088552-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-03-30 | — | — | US | disclosed |
| US-9376443-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| CN-104529884-A | Green synthetic method for preparation of N-alkyl pyridone | UNIV WENZHOU | 2015-04-22 | — | — | CN | disclosed |
| US-8987279-B2 | Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2013-09-19 | — | — | US | disclosed |
| US-8450328-B2 | Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| EP-2321321-B1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-20190031668-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-20170088552-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4206/4885KDM4E 4513/4885ALDH1A1 1328/4885 |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | MAPT 4206/4885KDM4E 4513/4885ALDH1A1 1328/4885 |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4242/4885KDM4E 4563/4885ALDH1A1 1329/4885 |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | MAPT 4206/4885KDM4E 4513/4885ALDH1A1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.